AVITA Medical (RCEL) Hisse Özeti
AVITA Medical, Inc. iştirakleriyle birlikte Amerika Birleşik Devletleri, Japonya, Avrupa Birliği, Avustralya ve Birleşik Krallık'ta terapötik akut yara bakım şirketi olarak faaliyet göstermektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 5/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 0/6 |
| Temettüler | 0/6 |
RCEL Community Fair Values
Create NarrativeSee what 43 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AVITA Medical, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$5.10 |
| 52 Haftanın En Yüksek Seviyesi | US$7.12 |
| 52 Haftanın En Düşük Seviyesi | US$3.22 |
| Beta | 1.86 |
| 1 Aylık Değişim | 29.44% |
| 3 Aylık Değişim | -0.78% |
| 1 Yıllık Değişim | -1.35% |
| 3 Yıllık Değişim | -72.90% |
| 5 Yıllık Değişim | -73.53% |
| Halka arzdan bu yana değişim | -79.60% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 13
RCEL: Renewed Adoption Confidence Will Support Future Bullish Repricing
Analysts have raised their consolidated price target for AVITA Medical from $5.50 to $12, pointing to renewed confidence in RECELL adoption, expectations for organic revenue momentum, and views that the company has sufficient flexibility to support working capital needs. Analyst Commentary Recent research on AVITA Medical highlights a cluster of upbeat views around RECELL adoption, revenue momentum, and balance sheet flexibility, but also leaves room for questions about how consistently the company can execute against expectations.
Anlatı Güncellemesi • Jun 29
RCEL: Execution And Cash Strength Will Drive Recovery And Multiple Expansion
Analysts have raised their price target on AVITA Medical to $6.00 from $3.50. They point to recent quarterly revenue performance, expectations for execution in line with or better than guidance, and an improved cash position as key reasons for a higher fair value estimate and a lower future P/E assumption in updated models.Anlatı Güncellemesi • Jun 14
RCEL: Execution And Cash Strength Are Expected To Drive Future Upside
Narrative update The analyst price target for AVITA Medical has risen by $2.50 to $6.00, with analysts highlighting the recent stock pullback, the latest Q1 revenue level, and expectations for execution and cash position as key supports for this revision. Analyst Commentary Bullish analysts are pointing to the recent price target reset and rating change as a sign of renewed confidence in AVITA Medical after the latest quarterly update.Recent updates
Anlatı Güncellemesi • Jul 13
RCEL: Renewed Adoption Confidence Will Support Future Bullish Repricing
Analysts have raised their consolidated price target for AVITA Medical from $5.50 to $12, pointing to renewed confidence in RECELL adoption, expectations for organic revenue momentum, and views that the company has sufficient flexibility to support working capital needs. Analyst Commentary Recent research on AVITA Medical highlights a cluster of upbeat views around RECELL adoption, revenue momentum, and balance sheet flexibility, but also leaves room for questions about how consistently the company can execute against expectations.Anlatı Güncellemesi • Jun 29
RCEL: Execution And Cash Strength Will Drive Recovery And Multiple Expansion
Analysts have raised their price target on AVITA Medical to $6.00 from $3.50. They point to recent quarterly revenue performance, expectations for execution in line with or better than guidance, and an improved cash position as key reasons for a higher fair value estimate and a lower future P/E assumption in updated models.Anlatı Güncellemesi • Jun 14
RCEL: Execution And Cash Strength Are Expected To Drive Future Upside
Narrative update The analyst price target for AVITA Medical has risen by $2.50 to $6.00, with analysts highlighting the recent stock pullback, the latest Q1 revenue level, and expectations for execution and cash position as key supports for this revision. Analyst Commentary Bullish analysts are pointing to the recent price target reset and rating change as a sign of renewed confidence in AVITA Medical after the latest quarterly update.Anlatı Güncellemesi • May 31
RCEL: Market Recovery And Cash Progress Are Expected To Drive Upside
Analysts have slightly adjusted the AVITA Medical price target to reflect updated assumptions for growth, margins and future P/E. They continue to reference Street research that highlights improving execution, Lake Street’s higher $6 target, and Northland's $10 target supported by expectations for revenue recovery, cash progress and a large addressable market.
Anlatı Güncellemesi • May 10
RCEL: Low Market Penetration And FY27 Cash Breakeven Will Drive Repricing
Analysts have trimmed their price target for AVITA Medical to $5.49 from $5.52, reflecting updated assumptions on discount rate, revenue growth, profit margin, and future P/E after recent research highlighted low current market penetration, a roughly $1.3b total addressable market, reimbursement stabilization, and an outlook for potential cash breakeven during FY27. Analyst Commentary Recent research points to a mixed backdrop for AVITA Medical, with analysts updating their models around a roughly $1.3b total addressable market, low current market penetration of about 5%, and expectations tied to reimbursement trends and the path toward a potential cash breakeven during FY27.Anlatı Güncellemesi • Apr 25
RCEL: Market Penetration And Burn Preparedness Agreement Will Support Constructive Upside
Narrative Update on AVITA Medical The Analyst Price Target for AVITA Medical has been adjusted from $10.02 to about $10.16. Analysts point to updated views on revenue growth and profit margins, as well as recent Northland research highlighting market penetration, product differentiation, reimbursement trends and the path toward cash breakeven as key supports for this change.Anlatı Güncellemesi • Apr 11
RCEL: Reimbursement Stability And FY27 Cash Breakeven Frame Balanced Risk Reward Outlook
The analyst price target for AVITA Medical has been revised slightly higher to reflect an updated fair value of about $5.52, up from roughly $5.33. Analysts point to expectations for revenue growth, stable profit margins, and recent research citing product differentiation, reimbursement stabilization, and progress toward cash breakeven as key drivers of their refreshed view.Anlatı Güncellemesi • Mar 28
RCEL: Reimbursement Stability And FY27 Cash Breakeven Drive Bullish Rerating Potential
Analysts have trimmed their blended valuation for AVITA Medical, with the updated fair value estimate easing from about $5.44 to $5.33 per share. This reflects revised assumptions on revenue growth, profit margins, and a lower future P/E multiple informed by recent research that highlights both the pullback in the stock and expectations for double digit top line expansion over time.Anlatı Güncellemesi • Mar 13
RCEL: Reimbursement Stability And Cash Breakeven Path Will Underpin Renewed Market Confidence
Analysts have lifted their AVITA Medical price target to $10, supported by expectations for renewed double digit revenue growth from a roughly $1.3b addressable market, reimbursement stabilization, and a path to potential cash breakeven around FY27. Analyst Commentary Recent coverage has highlighted a mixed but generally constructive view on AVITA Medical, with the latest initiation pointing to a $10 price target.Anlatı Güncellemesi • Feb 27
RCEL: Refined Earnings Assumptions And Burn Data Will Support Constructive Upside
Analysts have nudged their average price target on AVITA Medical up by $0.50 per share, citing updated assumptions around revenue growth, profit margins and P/E multiples that modestly refine their valuation models. Analyst Commentary Recent bullish analysts have framed the $0.50 uplift in the average price target as a refinement rather than a wholesale reset.Anlatı Güncellemesi • Feb 13
RCEL: Ongoing Burn And Wound Data Will Support Constructive Long-Term Upside
Analysts have adjusted their price target on AVITA Medical to $10.07 from $14.10, reflecting updated views on fair value, discount rate, revenue growth and profit margin assumptions that are broadly consistent with recent Street research, including the modest target raise cited by Lake Street. Analyst Commentary Recent price target work on AVITA Medical points to a more constructive tone among bullish analysts, even if some models still embed conservative assumptions on execution and profitability.Anlatı Güncellemesi • Jan 30
RCEL: Elevated Expectations For 2026 Guidance Will Expose Fragile Market Confidence
Narrative Update: AVITA Medical Analysts have raised their price target on AVITA Medical to about US$3.61 from roughly US$3.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E as key factors behind the revised assessment. Analyst Commentary Even with a higher price target around US$3.61, bearish analysts remain cautious and describe the move as a fine tuning of assumptions rather than a strong endorsement of upside potential.Analiz Makalesi • Jan 24
There's No Escaping AVITA Medical, Inc.'s (NASDAQ:RCEL) Muted Revenues Despite A 26% Share Price Rise
AVITA Medical, Inc. ( NASDAQ:RCEL ) shareholders would be excited to see that the share price has had a great month...Anlatı Güncellemesi • Jan 16
RCEL: Two Year Revenue Guidance Reset Will Support Bullish Repricing
Analysts have adjusted their price target for AVITA Medical, reflecting a lower implied fair value of $6.98, down from $7.32. They cite updated assumptions around revenue growth, profit margins, and a reduced future P/E multiple.Analiz Makalesi • Nov 09
AVITA Medical, Inc. (NASDAQ:RCEL) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
AVITA Medical, Inc. ( NASDAQ:RCEL ) missed earnings with its latest quarterly results, disappointing overly-optimistic...Anlatı Güncellemesi • Nov 08
RCEL: Leadership Transition And Guidance Reset Will Drive Second Half Recovery
Analysts have lowered their price target for AVITA Medical from $8.00 to $4.00. They cite weaker-than-expected Q3 revenue, leadership changes, and the need to amend debt agreements as key factors in their revised outlook.Analiz Makalesi • Oct 03
AVITA Medical, Inc. (NASDAQ:RCEL) Surges 28% Yet Its Low P/S Is No Reason For Excitement
AVITA Medical, Inc. ( NASDAQ:RCEL ) shareholders would be excited to see that the share price has had a great month...Anlatı Güncellemesi • Sep 17
Medicare Resolution And Trauma Expansion Will Shape Future Wound Care
Analysts have markedly reduced AVITA Medical’s price target from $9.60 to $8.26 amid lowered guidance, recurring earnings misses, and ongoing reimbursement headwinds that are pressuring demand and raising solvency concerns despite management’s optimism for a second-half recovery. Analyst Commentary Materially lowered guidance has prompted a significant reset of expectations, but management maintains confidence in a second half recovery.Anlatı Güncellemesi • Aug 15
Medicare Resolution And Trauma Expansion Will Shape Future Wound Care
AVITA Medical’s consensus price target remains unchanged as analysts respond to materially reduced guidance and persistent reimbursement issues—with bulls viewing the lowered expectations as prudent and bears citing execution risks and near-term revenue headwinds—leaving the fair value steady at $9.60. Analyst Commentary Materially reduced guidance led to significant downward revisions in price targets.Analiz Makalesi • Aug 10
AVITA Medical, Inc. (NASDAQ:RCEL) Not Doing Enough For Some Investors As Its Shares Slump 25%
Unfortunately for some shareholders, the AVITA Medical, Inc. ( NASDAQ:RCEL ) share price has dived 25% in the last...Analiz Makalesi • May 29
Shareholders Will Probably Not Have Any Issues With AVITA Medical, Inc.'s (NASDAQ:RCEL) CEO Compensation
Key Insights AVITA Medical will host its Annual General Meeting on 4th of June CEO Jim Corbett's total compensation...
Yeni Anlatı • Apr 24
PermeaDerm And Cohealyx Will Open International Markets
Launching new products and expanding internationally are expected to drive significant revenue growth and market penetration.Analiz Makalesi • Mar 06
Investors Don't See Light At End Of AVITA Medical, Inc.'s (NASDAQ:RCEL) Tunnel
AVITA Medical, Inc.'s ( NASDAQ:RCEL ) price-to-sales (or "P/S") ratio of 3.5x might make it look like a strong buy...Analiz Makalesi • Dec 30
Is AVITA Medical (NASDAQ:RCEL) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Hissedar Getirileri
| RCEL | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 25.6% | -0.9% | -2.0% |
| 1Y | -1.4% | 34.1% | 17.2% |
Getiri vs. Endüstri: RCEL geçen yıl % 34.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: RCEL geçen yıl % 17.2 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| RCEL volatility | |
|---|---|
| RCEL Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: RCEL son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: RCEL 'nin haftalık oynaklığı ( 11% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| n/a | 226 | Cary Vance | avitamedical.com |
AVITA Medical, Inc. iştirakleriyle birlikte Amerika Birleşik Devletleri, Japonya, Avrupa Birliği, Avustralya ve Birleşik Krallık'ta terapötik bir akut yara bakım şirketi olarak faaliyet göstermektedir. Şirketin öncü ürünü, termal yanık yaralarının ve tam kalınlıktaki cilt defektlerinin tedavisinin yanı sıra stabil depigmente vitiligo lezyonlarının repigmentasyonu için kullanılan bir hücre toplama cihazı olan RECELL Sistemidir. Ayrıca, 1.920 cm2'ye kadar olan alanları tedavi edebilen RECALL otolog hücre toplama cihazı; 1.920 cm²'ye kadar olan alanları tedavi edebilen gelişmiş bir kullanım kolaylığı cihazı olan RECELL otolog hücre toplama cihazı; ve 480 cm2'ye kadar daha küçük yaraları tedavi etmek için RECELL GO sisteminin bir uzantısı olan RECELL GO mini otolog hücre toplama cihazının yanı sıra donör cilt hücrelerini ayrıştırmak için uygulanan basıncı kontrol eden ve yöneten ve hücre verimini optimize etmek ve hücre canlılığını artırmak için RECELL Enziminin inkübasyon süresini kontrol eden RECELL GO işleme cihazından oluşan RECELL GO otolog hücre toplama cihazı; ve 1.920 cm2'ye kadar alanları tedavi edebilen RECELL GO hazırlama kiti.
AVITA Medical, Inc. Temel Bilgiler Özeti
| RCEL temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$153.30m |
| Kazançlar(TTM) | -US$45.34m |
| Gelir(TTM) | US$72.35m |
2.2x
P/S Oranı-3.5x
F/K OranıRCEL aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| RCEL gelir tablosu (TTM) | |
|---|---|
| Gelir | US$72.35m |
| Gelir Maliyeti | US$13.48m |
| Brüt Kâr | US$58.86m |
| Diğer Giderler | US$104.20m |
| Kazançlar | -US$45.34m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 06, 2026
| Hisse başına kazanç (EPS) | -1.47 |
| Brüt Marj | 81.36% |
| Net Kâr Marjı | -62.67% |
| Borç/Özkaynak Oranı | -199.2% |
RCEL uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/17 04:58 |
| Gün Sonu Hisse Fiyatı | 2026/07/17 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
AVITA Medical, Inc. 13 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| John Hester | Bell Potter |
| Lyanne Harrison | BofA Global Research |
| Laura McGuigan | B. Riley Securities, Inc. |